T Cell-Specific Deficiency of Src Homology 2-Containing Protein Tyrosine Phosphatase 2 Ameliorates Psoriasis and Colitis by Promoting Treg Differentiation

Abstract

Psoriasis and ulcerative colitis are both autoimmune diseases with complex pathogenesis characterized by immune disorders. Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase that acts as a key regulator of immune cell-mediated inflammation. Although studies have described the role of SHP2 in autoimmune diseases, its influence on the development of regulatory T cells (Tregs) was undefined, which plays a critical role in immune homeostasis. Here, we found that imiquimod (IMQ)-induced psoriasis symptoms were milder in Lck-Cre;SHP2^f/f mice than those in SHP2^f/f mice, including reduced inflammatory cell infiltration and keratinocyte proliferation. The reduced Th17/Treg ratio in psoriasis models in Lck-Cre;SHP2^f/f mice suggests that SHP2 regulates the balance of Th17/Treg. In vitro, the deficiency of SHP2 promotes the differentiation of T cells into Tregs. In the model of adoptive transfer colitis, the SHP2-deficient CD4⁺CD25⁻CD45RB^high T cells differentiated into a greater number of Tregs within the recipient mice, resulting in attenuated symptoms of colitis. Moreover, cotransfer experiments confirmed that the deficiency of SHP2 does not affect the immunosuppressive function of Tregs. These findings establish that SHP2 reduces Treg differentiation and further confirm that SHP2 inhibitors could be utilized in the treatment of autoimmune diseases.

Keywords

adoptive transfer colitis / autoimmune disease / psoriasis / Src homology 2-containing protein tyrosine phosphatase 2 / Treg

References

[1] R. Parisi, I. Y. K. Iskandar, E. Kontopantelis, et al., “National, Regional, and Worldwide Epidemiology of Psoriasis: Systematic Analysis and Modelling Study,” BMJ 369 (2020): m1590.

[2] D. J. Veale and U. Fearon, “Psoriatic Arthritis 1 the Pathogenesis of Psoriatic Arthritis,” Lancet 391, no. 10136 (2018): 2273-2284.

[3] D. Yan, L. Afifi, C. Jeon, et al., “A Cross-Sectional Study of Psoriasis Triggers Among Different Ethno-Racial Groups,” Journal of the American Academy of Dermatology 77, no. 4 (2017): 756-758.

[4] C. Le Berre, S. Honap, and L. Peyrin-Biroulet, “Ulcerative Colitis,” Lancet 402, no. 10401 (2023): 571-584.

[5] S. S. C. Rao, C. D. Holdsworth, and N. W. Read, “Symptoms and Stool Patterns in Patients With Ulcerative-Colitis,” Gut 29, no. 3 (1988): 342-345.

[6] B. E. Sands, “From Symptom to Diagnosis: Clinical Distinctions Among Various Forms of Intestinal Inflammation,” Gastroenterology 126, no. 6 (2004): 1518-1532.

[7] C. E. M. Griffiths, A. W. Armstrong, J. E. Gudjonsson, et al., “Psoriasis,” Lancet 397, no. 10281 (2021): 1301-1315.

[8] C. R. H. Hedin, E. Sonkoly, M. Eberhardson, et al., “Inflammatory Bowel Disease and Psoriasis: Modernizing the Multidisciplinary Approach,” Journal of Internal Medicine 290, no. 2 (2021): 257-278.

[9] J. Guo, H. Y. Zhang, W. R. Lin, et al., “Signaling Pathways and Targeted Therapies for Psoriasis,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 437.

[10] M. F. Neurath, “Strategies for Targeting Cytokines in Inflammatory Bowel Disease,” Nature Reviews Immunology 24, no. 8 (2024): 559-576.

[11] T. Kobayashi, B. Siegmund, C. L. Berre, et al., “Ulcerative Colitis,” Nature Reviews Disease Primers 6, no. 1 (2020): 1606-1619.

[12] A. K. Abbas, C. Benoist, J. A. Bluestone, et al., “Regulatory T Cells: Recommendations to Simplify the Nomenclature,” Nature Immunology 14, no. 4 (2013): 307-308.

[13] L. M. Williams and A. Y. Rudensky, “Maintenance of the Foxp3-dependent Developmental Program in Mature Regulatory T Cells Requires Continued Expression of Foxp3,” Nature Immunology 8, no. 3 (2007): 277-284.

[14] A. Liston and D. H. D. Gray, “Homeostatic Control of Regulatory T Cell Diversity,” Nature Reviews Immunology 14, no. 3 (2014): 154-165.

[15] S. Sakaguchi, T. Yamaguchi, T. Nomura, et al., “Regulatory T Cells and Immune Tolerance,” Cell 133, no. 5 (2008): 775-787.

[16] D. A. A. Vignali, L. W. Collison, and C. J. Workman, “How Regulatory T Cells Work,” Nature Reviews Immunology 8, no. 7 (2008): 523-532.

[17] M. A. Alyanakian, S. You, D. Damotte, et al., “Diversity of Regulatory CD4 T Cells Controlling Distinct Organ-Specific Autoimmune Diseases,” Proceedings of the National Academy of Sciences of the United States of America 100, no. 26 (2003): 15806-15811.

[18] C. R. Grant, R. Liberal, G. Mieli-Vergani, et al., “Regulatory T-Cells in Autoimmune Diseases: Challenges, Controversies and—yet—Unanswered Questions,” Autoimmunity Reviews 14, no. 9 (2015): 105-116.

[19] O. Zharkova, T. Celhar, P. D. Cravens, et al., “Pathways Leading to an Immunological Disease: Systemic Lupus Erythematosus,” Rheumatology 56 (2017): 55-66.

[20] L. Nussbaum, Y. L. Chen, and G. S. Ogg, “Role of Regulatory T Cells in Psoriasis Pathogenesis and Treatment,” British Journal of Dermatology 184, no. 1 (2021): 14-24.

[21] Y. X. Deng, C. Chang, and Q. J. Lu, “The Inflammatory Response in Psoriasis: A Comprehensive Review,” Clinical Reviews in Allergy & Immunology 50, no. 3 (2016): 377-389.

[22] T. Hartwig, P. Zwicky, B. Schreiner, et al., “Regulatory T Cells Restrain Pathogenic T Helper Cells During Skin Inflammation,” Cell Reports 25, no. 13 (2018): 3564.

[23] K. Stockenhuber, A. N. Hegazy, N. R. West, et al., “Foxp3 T Reg Cells Control Psoriasiform Inflammation by Restraining an IFN-I-driven CD8 T Cell Response,” Journal of Experimental Medicine 215, no. 8 (2018): 1987-1998.

[24] L. Zhang, Y. Li, X. Yang, et al., “Characterization of Th17 and FoxP3 Treg Cells in Paediatric Psoriasis Patients,” Scandinavian Journal of Immunology 83, no. 3 (2016): 174-180.

[25] X. Y. Wang, X. Y. Chen, J. Li, et al., “MiR-200a Expression in CD4+T Cells Correlates With the Expression of Th17/Treg Cells and Relevant Cytokines in Psoriasis vulgaris: A Case Control Study,” Biomedicine & Pharmacotherapy 93 (2017): 1158-1164.

[26] H. Sugiyama, R. Gyulai, E. Toichi, et al., “Dysfunctional Blood and Target Tissue CD4 CD25 Regulatory T Cells in Psoriasis: Mechanism Underlying Unrestrained Pathogenic Effector T Cell Proliferation,” Journal of Immunology 174, no. 1 (2005): 164-173.

[27] J. Kim and J. G. Krueger, “The Immunopathogenesis of Psoriasis,” Dermatologic Clinics 33, no. 1 (2015): 13.

[28] B. Singh, S. Read, C. Asseman, et al., “Control of Intestinal Inflammation by Regulatory T Cells,” Immunological Reviews 182 (2001): 190-200.

[29] M. C. Fantini, C. Becker, I. Tubbe, et al., “Transforming Growth Factor β Induced FoxP3+ Regulatory T Cells Suppress Th1 Mediated Experimental Colitis,” Gut 55, no. 5 (2006): 671-680.

[30] P. Chamouard, F. Monneaux, Z. Richert, et al., “Diminution of Circulating CD₄+CD₂₅ T Cells in Naïve Crohn's Disease,” Digestive Diseases and Sciences 54, no. 10 (2009): 2084-2093.

[31] N. Eastaff-Leung, N. Mabarrack, A. Barbour, et al., “Foxp3 Regulatory T Cells, Th17 Effector Cells, and Cytokine Environment in Inflammatory Bowel Disease,” Journal of Clinical Immunology 30, no. 1 (2010): 80-89.

[32] R. J. He, Z. H. Yu, R. Y. Zhang, et al., “Protein Tyrosine Phosphatases as Potential Therapeutic Targets,” Acta Pharmacologica Sinica 35, no. 10 (2014): 1227-1246.

[33] Z. D. Song, M. J. Wang, Y. Ge, et al., “Tyrosine Phosphatase SHP2 Inhibitors in Tumor-targeted Therapies,” Acta Pharmaceutica Sinica B 11, no. 1 (2021): 13-29.

[34] J. Pan, L. S. Zhou, C. Y. Zhang, et al., “Targeting Protein Phosphatases for the Treatment of Inflammation-Related Diseases: From Signaling to Therapy,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 117.

[35] Z. G. Cai, J. J. Kotzin, B. Ramdas, et al., “Inhibition of Inflammatory Signaling in Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis,” Cell Stem Cell 23, no. 6 (2018): 833.

[36] F. Shao, Q. Liu, Y. Zhu, et al., “Targeting Chondrocytes for Arresting Bony Fusion in Ankylosing Spondylitis,” Nature Communications 12, no. 1 (2021): 6540.

[37] K. Maeshima, S. M. Stanford, D. Hammaker, et al., “Abnormal Enhancer Methylation Promotes Rheumatoid Arthritis Fibroblast-Like Synoviocyte Aggressiveness and Joint Inflammation,” JCI Insight 1, no. 7 (2016): e86580.

[38] Y. Ding, Z. J. Ouyang, C. Y. Zhang, et al., “Tyrosine Phosphatase SHP2 Exacerbates Psoriasis-Like Skin Inflammation in Mice via ERK5-Dependent NETosis,” MedComm 3, no. 1 (2022): e120.

[39] R. Paccoud, C. Saint-Laurent, E. Piccolo, et al., “SHP2 drives Inflammation-Triggered Insulin Resistance by Reshaping Tissue Macrophage Populations,” Science Translational Medicine 13, no. 591 (2021): eabe2587.

[40] F. P. Wang, Y. H. Yang, Z. X. Li, et al., “Mannan-Binding Lectin Regulates the Th17/Treg Axis Through JAK/STAT and TGF-β/SMAD Signaling Against Infection,” Journal of Inflammation Research 15 (2022): 1797-1810.

[41] H. H. Ni, H. L. Zhang, L. Li, et al., “T Cell-Intrinsic STING Signaling Promotes Regulatory T Cell Induction and Immunosuppression by Upregulating FOXP₃ Transcription in Cervical Cancer,” Journal for Immunotherapy of Cancer 10, no. 9 (2022): e005151.

[42] C. L. Yu, Y. J. Jin, and S. J. Burakoff, “Cytosolic Tyrosine Dephosphorylation of STAT5—Potential Role of SHP-2 in STAT₅ Regulation,” Journal of Biological Chemistry 275, no. 1 (2000): 599-604.

[43] G. R. Lee, “The Balance of Th17 Versus Treg Cells in Autoimmunity,” International Journal of Molecular Sciences 19, no. 3 (2018): 730.

[44] H. J. Bovenschen, P. C. van de Kerkhof, P. E. van Erp, et al., “Foxp3+Regulatory T Cells of Psoriasis Patients Easily Differentiate Into IL-17A-Producing Cells and Are Found in Lesional Skin,” Journal of Investigative Dermatology 131, no. 9 (2011): 1853-1860.

[45] Y. Y. Zhu, Z. G. Wu, W. Yan, et al., “Allosteric Inhibition of SHP2 Uncovers Aberrant TLR7 Trafficking in Aggravating Psoriasis,” Embo Molecular Medicine 14, no. 3 (2022): e14455.

[46] M. J. Wang, T. H. Li, Z. J. Ouyang, et al., “SHP2 Allosteric Inhibitor TK-453 Alleviates Psoriasis-Like Skin Inflammation in Mice via Inhibition of IL-23/Th17 Axis,” IScience 25, no. 4 (2022): 104009.

[47] A. Izcue, J. L. Coombes, and F. Powrie, “Regulatory T Cells Suppress Systemic and Mucosal Immune Activation to Control Intestinal Inflammation,” Immunological Reviews 212 (2006): 256-271.

[48] W. Hueber, B. E. Sands, S. Lewitzky, et al., “Secukinumab, a Human Anti-IL-17A Monoclonal Antibody, for Moderate to Severe Crohn's Disease: Unexpected Results of a Randomised, Double-Blind Placebo-Controlled Trial,” Gut 61, no. 12 (2012): 1693-1700.

[49] A. G. A. Kolios, L. Biedermann, A. Weber, et al., “Paradoxical Ulcerative Colitis During adalimumab Treatment of Psoriasis Resolved by Switch to Ustekinumab,” British Journal of Dermatology 178, no. 2 (2018): 551-555.

[50] R. P. Hirten, M. Iacucci, S. Shah, et al., “Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders,” Clinical Gastroenterology and Hepatology 16, no. 9 (2018): 1374-1384.

[51] J. K. Kolls and S. A. Khader, “The Role of Th17 Cytokines in Primary Mucosal Immunity,” Cytokine & Growth Factor Reviews 21, no. 6 (2010): 443-448.

[52] B. Ahluwalia, M. K. Magnusson, and L. Öhman, “Mucosal Immune System of the Gastrointestinal Tract: Maintaining Balance Between the Good and the Bad,” Scandinavian Journal of Gastroenterology 52, no. 11 (2017): 1185-1193.

[53] C. Raffin, L. T. Vo, and J. A. Bluestone, “T Cell-Based Therapies: Challenges and Perspectives,” Nature Reviews Immunology 20, no. 3 (2020): 158-172.

[54] T. S. Sumida, N. T. Cheru, and D. A. Hafler, “The Regulation and Differentiation of Regulatory T Cells and Their Dysfunction in Autoimmune Diseases,” Nature Reviews Immunology 24, no. 7 (2024): 503-517.

[55] S. Sakaguchi, N. Mikami, J. B. Wing, et al., “Regulatory T Cells and Human Disease,” Annual Review of Immunology 38 (2020): 541-566.

[56] L. M. R. Ferreira, Y. D. Muller, J. A. Bluestone, et al., “Next-Generation Regulatory T Cell Therapy,” Nature Reviews Drug Discovery 18, no. 10 (2019): 749-769.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.